Reading GEHC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GEHC free→Reading GEHC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GEHC free→
NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been fairly steady, though the capital stance is capital unfriendly. The sector backdrop is a headwind, and risk is moderate. Peer multiples imply a price about 40% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while earnings quality is fragile. If GEHC reverses course and raises guidance next quarter, that could signal a sharp positive shift. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $63.23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $65 GEHC trades at 14× p/e, below its 23× p/e peer median. Our $105 fair value sits above the price; medium confidence. Analysts: $65–$90. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 40% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 0.28x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.04 → $1.03 (-0.4% / 30d). 0 raised, 14 cut, 14 covering analysts.
1 upgrade, 0 downgrades / 30d, 0 maintained. 67% of analysts rate Buy.
1 PT revisions / 30d. Avg target 7.4% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$113.
How much price usually moves either way.
On a bad day, this stock has moved -$330.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,247.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This will indicate if GE HealthCare is struggling to meet its growth targets in a tough market.
Confirms:Q2 2026 revenue growth reported below 3.0% year over year.
Disproves:Q2 2026 revenue growth reported at or above 3.0% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Increase revenue growth
AI oncology push aligns with revenue growth objective.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On April 29, 2026 , GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2026 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$65.00 – $90.00 (median $80.00) · 8 analysts · as of 2026-05-21
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
GEHC GE HealthCare | Above typical Show detailsSector percentile: 89 of 100 | inexpensive | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on improving operating income through cost management and efficiency.
Ensure robust cash flow from operations to support financial stability.
Drive revenue growth through strategic initiatives and market expansion.
Why it matters: A lower EPS may show profit problems. This could lower investor confidence.
Confirms:Adjusted EPS reported below $0.85 in Q2 2026.
Disproves:Adjusted EPS reported at or above $0.85 in Q2 2026.
Why it matters: Better operating income means GE HealthCare is controlling costs. This may help investors.
Confirms:Operating income margin goes up from 13.5% to over 14.0% in Q2 2026.
Disproves:Operating income margin goes down or stays below 13.5% in Q2 2026.
Why it matters: A drop in cash flow may show problems in operations. This could hurt future investments.
Confirms:Cash flow from operations reported below $290 million in Q2 2026.
Disproves:Cash flow from operations reported at or above $290 million in Q2 2026.
Why it matters: A growing backlog shows strong demand. It also means more money for GE HealthCare in the future.
Confirms:The backlog was over $22 billion in Q2 2026.
Disproves:Backlog reported below $21.8 billion in Q2 2026.
Contract manufacturing agreement supports operational capabilities.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Kevin A. Lobo to serve as a director of the Company, effective immediately. Mr. Lobo’s term will expire at the Company’s 2026 Annual Meeting of Stockholders. The Board also appointed Mr. Lobo as a member of the Talent, Culture, and C…
Entry into a Material Definitive Agreement. On February 26, 2026, GE HealthCare Technologies Inc. (the “Company”) entered into a 364-Day Revolving Credit Agreement (the “New Revolving Credit Agreement”) among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders named therein, which provides for a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $0.5 billion. The New Revolving Credit Facility replaces the 364-Day Revolving Credi…
Termination of a Material Definitive Agreement. In connection with the Company’s entry into the New Revolving Credit Agreement, the 2025 364-Day Revolving Credit Agreement, which provided for a $0.5 billion 364-day senior unsecured revolving credit facility, was terminated without penalty on February 26, 2026.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in